Functional rest through intensive treatment with insulin and potassium channel openers preserves residual β-cell function and mass in acutely diabetic BB rats

Hormone and Metabolic Research

Volumn 32, Issue 7, 2000, Pages 294-300

  Rasmussen, S B ^a   Sorensen, T S ^a   Hansen, J B ^b   Mandrup Poulsen, T ^c   Hornum, L ^a   Markholst, H ^a  

^a HAGEDORN RESEARCH INSTITUTE   (Denmark)

^b NOVO NORDISK A S   (Denmark)

^c STENO DIABETES CENTER   (Denmark)

Author keywords

Animal Models; Autoimmunity; IDDM; Ion Channels; Type I Diabetes; Cell Rest

Indexed keywords

DIAZOXIDE; GLUCOSE; INSULIN; NNC 55 0118; POTASSIUM CHANNEL AFFECTING AGENT; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; AUTOIMMUNITY; CONTROLLED STUDY; DIABETES MELLITUS; DRUG POTENCY; IMMUNOHISTOCHEMISTRY; MALE; NONHUMAN; POTASSIUM TRANSPORT; PRIORITY JOURNAL; RAT;

ANIMALIA;

EID: 0033840593     PISSN: 00185043     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-978639     Document Type: Article

References (36)

1. Type I diabetes mellitus. A chronic autoimmune disease
2. Beta-cell dysfunction induced by chronic hyperglycemia. Current ideas on mechanism of impaired glucose-induced insulin secretion
3. High-glucose stimulation of 64000-Mr islet cell autoantigen expression
4. Regulation of glutamic acid decarboxylase diabetes autoantigen expression in highly purified isolated islets from Macaca nemestrina
5. Metabolic state of the pancreas affects endpoint titre in the islet cell antibody assay
6. Insulin-dependent diabetes mellitus as an autoimmune disease
7. Remission in IDDM: Prospective study of basal C-peptide and insulin dose in 268 consecutive patients
8. Reduction of diabetes incidence of BB Wistar rats by early prophylactic insulin treatment of diabetes-prone animals
9. Diabetes prevention in BB rats by inhibition of endogenous insulin secretion
10. Insulitis and diabetes in NOD mice reduced by prophylactic insulin therapy
11. Insulin sensitivity in newly diagnosed type I diabetics after ketoacidosis and after three months of insulin therapy
12. Repair of pancreatic beta-cells. A relevant phenomenon in early IDDM?
13. Effect of intensive therapy on residual beta-cell function in patients with type I diabetes in the diabetes control and complications trial. A randomized, controlled trial
14. Expression of the 64 kDa/glutamine acid decarboxylase rat islet cell autoantigen is influenced by the rate of insulin secretion
15. Modulation of beta-cell activity and its influence on islet cell antibody (ICA) and islet cell surface antibody (ICSA) reactivity
16. Diazoxide treatment at onset preserves residual insulin secretion in adults with autoimmune diabetes
17. Effects of sulphonylureas and diazoxide on insulin secretion and nucleotide-sensitive channels in an insulin-secreting cell line
18. + channel activators, RP 52891, cromakalim and diazoxide, on the plasma insulin level, plasma renin activity and blood pressure in rats
19. Cationic and secretory effects of BPDZ 44 and diazoxide in rat pancreatic islets
20. Effect of diazoxide on plasma renin activity in hypertensive patients
21. A brief review of the development of diazoxide as an antihypertensive agent
22. Severe polydipsia and antidiuresis produced by diazoxide
23. Dilutional hyponatremia due to diazoxide-produced polydipsia
24. Hematological side-effects of diazoxide
25. Potassium channel openers stimulated DNA synthesis in mouse epidermal keratinocyte and whole hair follicle cultures
26. Prevalence of residual beta-cell function and its metabolic consequences in type I (insulin-dependent) diabetes
27. Correlation between minimal secretory capacity of pancreatic β-cells and stability of diabetic control
28. Relationships among islet cell antibodies, residual β-cell function, and metabolic control in patients with insulin-dependent diabetes mellitus of long duration: Use of a sensitive C-peptide radioimmunoassay
29. Residual β-cell function and HLA-A24 in IDDM. Markers of glycemic control and subsequent development of diabetic retinopathy
30. Are the implications of the Diabetes Control and Complications Trial (DCCT) feasible in daily clinical practice?
31. Metabolic control and quality-of-life self-assessment in adolescents with IDDM
32. Measurement of rat insulin. Enzyme-linked immunosorbent assay with increased sensitivity, high accuracy, and greater practicability than established radioimmunoassay
33. β-Cell maturation leads to in vitro sensitivity to cytotoxins
34. DNA fluorometric assay in 96-well tissue culture plates using Hoechst 33258 after cell lysis by freezing in distilled water
35. Loss of insulin response to glucose but not arginine during the development of autoimmune diabetes in BB/W rats: Relationships to islet volume and glucose transport rate
36. Curing BB rats of freshly manifested diabetes by short-term treatment with a combination of a monoclonal anti-interleukin 2 receptor antibody and a subtherapeutic dose of cyclosporin A